An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NeoGenomics, Inc. (NASDAQ: NEO) will report its Q4 and full year 2023 financial results on February 20, 2024. A webcast and conference call will be held to discuss the results and recent highlights. The live webcast can be accessed on the Investor Relations section of their website. The call can also be accessed via telephone with the provided participant access code.
Positive
None.
Negative
None.
FT. MYERS, Fla.--(BUSINESS WIRE)--
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 822624.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
When will NeoGenomics report its Q4 and full year 2023 financial results?
NeoGenomics will report its Q4 and full year 2023 financial results on February 20, 2024.
How can I access the live webcast of the financial results discussion?
The live webcast can be accessed by visiting the Investor Relations section of NeoGenomics website.
How can I access the conference call to discuss the financial results?
The conference call can be accessed via telephone by dialing (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call with the participant access code 822624.
